Trial Profile
A retrospective study assessing relative dose intensity in patients treated with pazopanib for advanced/metastatic soft tissue sarcoma (STS).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jul 2016
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 21 Jul 2016 New trial record
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology